These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1934674)

  • 1. Comment on "Irreversible ocular toxicity from single challenge dose of desferrioxamine" by C. Bene et al.
    Yaqoob M; Prabhu P; Ahmad R
    Clin Nephrol; 1991 Sep; 36(3):155. PubMed ID: 1934674
    [No Abstract]   [Full Text] [Related]  

  • 2. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 4. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
    Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
    Martín C; Lens XM; Prieto A; Alonso R; Correa B; Arcocha V; Soto A
    An Otorrinolaringol Ibero Am; 1994; 21(2):193-8. PubMed ID: 8209972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tissue overload of aluminum in hemodialysis patients. The desferrioxamine test].
    Simon P; Ang KS; Tanquerel T; Allain P; Mauras Y
    Nouv Presse Med; 1982 Jan; 11(3):209. PubMed ID: 7058145
    [No Abstract]   [Full Text] [Related]  

  • 11. Desferrioxamine infusion test.
    Gilli P; Malacarne F; Storari A; Brancaccio D; Gallieni M; Andriani M; Piccoli A; Nordio M
    Nephrol Dial Transplant; 1987; 2(1):54-5. PubMed ID: 3110700
    [No Abstract]   [Full Text] [Related]  

  • 12. [Poisoning of retinal pigment epithelium by deferoxamine. A case report].
    Charton N; Sahel JA; Flament J
    Bull Soc Ophtalmol Fr; 1990; 90(6-7):599-602. PubMed ID: 2225255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 14. Desferrioxamine infusion test.
    Soler Amigo J; Modol Gort J; Garcia Aznar A
    Nephrol Dial Transplant; 1987; 2(5):381. PubMed ID: 3122122
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 17. Side-effects of desferrioxamine in dialysis patients.
    Boelaert JR; de Locht M
    Nephrol Dial Transplant; 1993; 8 Suppl 1():43-6. PubMed ID: 8389020
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 20. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.